{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:42:37Z","timestamp":1777675357471,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00105-024-05376-x","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T07:02:07Z","timestamp":1720767727000},"page":"815-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neues in der Diagnostik und Therapie der aktinischen Keratose","Update in the diagnosis and treatment of actinic keratosis"],"prefix":"10.1007","volume":"75","author":[{"given":"Markus V.","family":"Heppt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"6","key":"5376_CR1","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/jcm11061654","volume":"11","author":"MV Heppt","year":"2022","unstructured":"Heppt MV et al (2022) Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Clin Med 11(6):1654","journal-title":"J Clin Med"},{"key":"5376_CR2","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.ejcskn.2023.100004","volume":"1","author":"U Leiter","year":"2023","unstructured":"Leiter\u00a0U et\u00a0al (2023) German S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d; Long version of the update 2023. EJC Skin Cancer 1:100007","journal-title":"EJC Skin Cancer"},{"issue":"10","key":"5376_CR3","first-page":"1249","volume":"21","author":"MV Heppt","year":"2023","unstructured":"Heppt\u00a0MV et\u00a0al (2023) S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d\u2014update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen\u2019s disease), occupational disease and structures of care. J\u00a0Dtsch Dermatol Ges 21(10):1249\u20131262","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"5376_CR4","first-page":"1422","volume":"21","author":"U Leiter","year":"2023","unstructured":"Leiter\u00a0U et\u00a0al (2023) S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d\u2014update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. J\u00a0Dtsch Dermatol Ges 21(11):1422\u20131433","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"5376_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/jdv.19897","volume":"38","author":"L Kandolf","year":"2024","unstructured":"Kandolf L et al (2024) European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europeenne des Medecins Specialistes). J Eur Acad Dermatol Venereol 38(6):1024-1047","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5376_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cpdd.1368","volume":"13","author":"J DuBois","year":"2024","unstructured":"DuBois\u00a0J et\u00a0al (2024) Pharmacokinetics, Safety, and Tolerability of a\u00a0Single 5\u2011Day Treatment of Tirbanibulin Ointment 1\u202f% in 100\u202fcm(2) : A\u00a0Phase\u00a01 Maximal-Use Trial in Patients with Actinic Keratosis. Clin Pharmacol Drug Dev 13(2):208\u2013218","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"5376_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/jdv.14512","volume":"32","author":"L Schmitz","year":"2018","unstructured":"Schmitz\u00a0L et\u00a0al (2018) Actinic keratoses show variable histological basal growth patterns\u2014a\u00a0proposed classification adjustment. J\u00a0Eur Acad Dermatol Venereol 32(5):745\u2013751","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"18","key":"5376_CR8","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.3390\/cancers15184457","volume":"15","author":"F Daxenberger","year":"2023","unstructured":"Daxenberger F et al (2023) Innovation in Actinic Keratosis Assessment: Artificial Intelligence-Based Approach to LC-OCT PRO Score Evaluation. Cancers (Basel) 15(18):4457","journal-title":"Cancers (Basel)"},{"issue":"9","key":"5376_CR9","doi-asserted-by":"publisher","first-page":"e1131","DOI":"10.1111\/jdv.19147","volume":"37","author":"F Lacarrubba","year":"2023","unstructured":"Lacarrubba\u00a0F et\u00a0al (2023) Line-field confocal optical coherence tomography in the treatment monitoring of actinic keratosis with tirbanibulin: A\u00a0pilot study. J\u00a0Eur Acad Dermatol Venereol 37(9):e1131\u2013e1133","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"5376_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2021.2779","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb\u00a0T et\u00a0al (2021) Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis: A\u00a0Systematic Review and Network Meta-analysis. JAMA Dermatol 157(9):1066\u20131077","journal-title":"JAMA Dermatol"},{"key":"5376_CR11","doi-asserted-by":"publisher","first-page":"104031","DOI":"10.1016\/j.pdpdt.2024.104031","volume":"46","author":"S Saenz-Guirado","year":"2024","unstructured":"Saenz-Guirado\u00a0S et\u00a0al (2024) Home- vs clinic-based daylight photodynamic therapy with 5\u2011aminolevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A\u00a0randomized, single-blind, prospective study. Photodiagnosis Photodyn Ther 46:104031","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"4","key":"5376_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jdv.15422","volume":"33","author":"S Karrer","year":"2019","unstructured":"Karrer\u00a0S et\u00a0al (2019) Methyl aminolevulinate daylight photodynamic therapy applied at home for non-hyperkeratotic actinic keratosis of the face or scalp: an open, interventional study conducted in Germany. J\u00a0Eur Acad Dermatol Venereol 33(4):661\u2013666","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"5376_CR13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/jdv.19687","volume":"38","author":"S Caccavale","year":"2024","unstructured":"Caccavale\u00a0S et\u00a0al (2024) Keratolytics can replace curettage in daylight photodynamic therapy for actinic keratosis on the face\/scalp: A\u00a0randomized clinical trial. J\u00a0Eur Acad Dermatol Venereol 38(3):594\u2013601","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"5376_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt\u00a0A et\u00a0al (2021) Phase\u00a03 Trials of Tirbanibulin Ointment for Actinic Keratosis. N\u00a0Engl J Med 384(6):512\u2013520","journal-title":"N Engl J Med"},{"issue":"2","key":"5376_CR15","first-page":"225","volume":"60","author":"LF Pomi","year":"2024","unstructured":"Pomi LF et al (2024) Tirbanibulin 1\u202f% Ointment for Actinic Keratosis: Results from a Real-Life Study. Med (Kaunas) 60(2):225","journal-title":"Med (Kaunas)"},{"issue":"12","key":"5376_CR16","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/ph16121686","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E et al (2023) Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1\u202f% Ointment: A Clinical Perspective on Actinic Keratoses. Pharmaceuticals (Basel) 16(12):1686","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"5376_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/ajd.14151","volume":"64","author":"M Mansilla-Polo","year":"2023","unstructured":"Mansilla-Polo\u00a0M et\u00a0al (2023) Effectiveness, safety and satisfaction of 1\u202f% tirbanibulin ointment in the treatment of actinic keratoses: A\u00a0prospective study in real clinical practice. Australas J Dermatol 64(4):560\u2013564","journal-title":"Australas J Dermatol"},{"issue":"14","key":"5376_CR18","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.3390\/jcm12144837","volume":"12","author":"MC Kirchberger","year":"2023","unstructured":"Kirchberger MC et al (2023) Tirbanibulin 1\u202f% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study. J Clin Med 12(14):4837","journal-title":"J Clin Med"},{"issue":"9","key":"5376_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/ced\/llad171","volume":"48","author":"C Abril-Perez","year":"2023","unstructured":"Abril-Perez\u00a0C et\u00a0al (2023) Successful treatment of field cancerization on the dorsum of the hands with 1\u202f% tirbanibulin ointment. Clin Exp Dermatol 48(9):1048\u20131050","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"5376_CR20","first-page":"1218","volume":"15","author":"MA Dohil","year":"2016","unstructured":"Dohil\u00a0MA (2016) Efficacy, Safety, and Tolerability of 4\u202f% 5\u2011Fluorouracil Cream in a\u00a0Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5\u202f% 5\u2011Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis. J\u00a0Drugs Dermatol 15(10):1218\u20131224","journal-title":"J Drugs Dermatol"},{"key":"5376_CR21","doi-asserted-by":"publisher","first-page":"100661","DOI":"10.1016\/j.curtheres.2021.100661","volume":"96","author":"E Stockfleth","year":"2022","unstructured":"Stockfleth\u00a0E, Begeault\u00a0N, Delarue\u00a0A (2022) The Overall Number of Actinic Keratosis Lesions Is Not Predictable by the Number of Visible Lesions: Consequences for Field-Directed Therapies. Curr Ther Res Clin Exp 96:100661","journal-title":"Curr Ther Res Clin Exp"},{"issue":"12","key":"5376_CR22","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1111\/jdv.12782","volume":"29","author":"K Peris","year":"2015","unstructured":"Peris\u00a0K et\u00a0al (2015) Efficacy of imiquimod 3.75\u202f% from Lmax according to the number of actinic keratosis lesions. J\u00a0Eur Acad Dermatol Venereol 29(12):2470\u20132473","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5376_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s13555-021-00668-9","volume":"12","author":"E Stockfleth","year":"2022","unstructured":"Stockfleth\u00a0E, Begeault\u00a0N, Delarue\u00a0A (2022) Intensity of Local Skin Reactions During 5\u2011Fluorouracil Treatment Related to the Number of Actinic Keratosis Lesions: A\u00a0Post Hoc, Exploratory Analysis. Dermatol Ther (Heidelb) 12(2):467\u2013479","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"5376_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s13555-023-00902-6","volume":"13","author":"E Stockfleth","year":"2023","unstructured":"Stockfleth\u00a0E et\u00a0al (2023) Severity of Local Skin Reactions with 4\u202f% 5\u2011Fluorouracil Plus Emollient versus 4\u202f% 5\u2011Fluorouracil Alone in Patients with Actinic Keratosis: A\u00a0Single-Blind Randomised Trial. Dermatology Ther 13(4):1013\u20131027","journal-title":"Dermatology Ther"},{"issue":"2","key":"5376_CR25","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1302a151","volume":"13","author":"G Briatico","year":"2023","unstructured":"Briatico G et al (2023) Real-World Experience With Topical 5\u2011Fluorouracil 4\u202f% (40\u202fmg\/g) Cream for the Treatment of Actinic Keratosis. Dermatol Pract Concept 13(2):e2023151","journal-title":"Dermatol Pract Concept"},{"issue":"9","key":"5376_CR26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMoa2203086","volume":"388","author":"NC Allen","year":"2023","unstructured":"Allen\u00a0NC et\u00a0al (2023) Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N\u00a0Engl J Med 388(9):804\u2013812","journal-title":"N Engl J Med"},{"issue":"9","key":"5376_CR27","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.transproceed.2023.06.016","volume":"55","author":"H Zhang","year":"2023","unstructured":"Zhang\u00a0H et\u00a0al (2023) Oral Nicotinamide for Actinic Keratosis Prevention in Kidney Transplant Recipients: A\u00a0Pilot Double-Blind, Randomized, Placebo-Controlled Trial. Transplant Proc 55(9):2079\u20132084","journal-title":"Transplant Proc"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05376-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:03:43Z","timestamp":1727791423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05376-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5376"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05376-x","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"29 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.V.\u00a0Heppt<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Almirall zur Unterst\u00fctzung in der Durchf\u00fchrung von klinischen Studien. \u2013\u00a0Honorare f\u00fcr Vortr\u00e4ge von Biofrontera, Galderma, Almirall, Honorare f\u00fcr Beratungen und Adboards: Pierre Fabre, InfectoPharm.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Gesch\u00e4ftsf\u00fchrender Oberarzt an der Hautklinik des Uniklinikums Erlangen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}